肿瘤学护士转移性结直肠癌新型靶向药物指南
An oncology nurses' guide to new targeted agents for metastatic colorectal cancer.
作者信息
McIntyre Keith
机构信息
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD.
出版信息
Clin J Oncol Nurs. 2015 Oct;19(5):571-9. doi: 10.1188/15.CJON.571-579.
BACKGROUND
Colorectal cancer (CRC) that has metastasized before being discovered, or reoccurs following surgery, remains a major treatment challenge. Trials have established the usefulness of antiangiogenic agents and new regimens in prolonging survival in patients with advanced disease. In the United States, the antiangiogenic agents approved for treating metastatic CRC often are combined with traditional chemotherapeutic agents and include bevacizumab (Avastin®), ziv-aflibercept (Zaltrap®), and regorafenib (Stivarga®).
OBJECTIVES
This article reviews factors that guide the development of a nursing plan for monitoring and managing patients who are receiving antiangiogenic therapies.
METHODS
Regorafenib and ziv-aflibercept, two newer agents that nurses and other healthcare professionals may have had less experience with, were reviewed.
FINDINGS
The key to maximizing the potential benefit of these agents is understanding where these new therapies fit in the overall scheme of treatment options and how to help patients tolerate treatment.
背景
在发现前已发生转移或术后复发的结直肠癌（CRC）仍然是主要的治疗挑战。试验已证实抗血管生成药物和新方案在延长晚期疾病患者生存期方面的有效性。在美国，获批用于治疗转移性结直肠癌的抗血管生成药物通常与传统化疗药物联合使用，包括贝伐单抗（阿瓦斯汀®）、 阿柏西普（Zaltrap®）和瑞戈非尼（Stivarga®）。
目的
本文综述了指导制定护理计划以监测和管理接受抗血管生成治疗患者的相关因素。
方法
对瑞戈非尼和阿柏西普这两种护士及其他医疗保健专业人员可能经验较少的新型药物进行了综述。
结果
使这些药物的潜在益处最大化的关键在于了解这些新疗法在整体治疗方案中的位置以及如何帮助患者耐受治疗。
Zotero 插件